As an affiliate of GobyMeds, I earn a commission from qualifying purchases. Black Friday code BF26GP: $50 off a new patient's first order, not refills; type it at checkout. Ends Dec 2 at 11:59 p.m. Pacific.

Semaglutide Before and After: Weight Loss Results by Month

In STEP 1, weekly semaglutide 2.4 mg plus lifestyle intervention produced 14.9% mean weight loss at 68 weeks.

Trial endpoints, dose escalation and withdrawal studies explain what these averages can and cannot tell you about your own timeline.

July 17, 202612 min read

By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.

Summarize this article with

Editorial lifestyle photograph illustrating semaglutide before-and-after weight loss timeline

In STEP 1, adults without diabetes taking weekly semaglutide 2.4 mg plus lifestyle intervention lost a mean 14.9% of body weight at 68 weeks.

Trial averages do not predict your monthly result. Wegovy HD (7.2 mg) produced 20.7% mean weight loss at 72 weeks in STEP UP's as-intended analysis.

Separately, about 31% of participants assigned 7.2mg achieved at least 25% weight loss at 72 weeks in the main analysis. The original-study plain-language summary distinguishes these results.

The 31% figure uses a different threshold from a 20%-loss responder rate. Below, the injection schedule and withdrawal studies explain timing without promising an individual outcome.

Compare semaglutide forms, plan prices and payment terms when discussing access with your prescriber.

Your next step

Use this guide to prepare your questions. Talk to your prescriber before you change a medication or a dose.

Understand results over time →

What does the Wegovy injection timeline show?

The Wegovy prescribing information gradually increases the weekly injection dose to reduce gastrointestinal reactions.

This is a labelled dosing schedule, not a month-by-month weight-loss forecast. It does not describe oral semaglutide or a compounded formulation.

What does the Wegovy injection timeline show?
Wegovy injection periodLabelled weekly doseHow to read it
Weeks 1-40.25 mgStarting dose
Weeks 5-80.5 mgDose escalation
Weeks 9-121 mgDose escalation
Weeks 13-161.7 mgDose escalation
Week 17 onwardMaintenance depends on indication, response and tolerabilityYour prescriber selects the dose; escalation may be delayed if a dose is not tolerated
Important

Your prescriber may change the schedule based on tolerability. A trial endpoint is not a promised result at a particular month, and branded Wegovy results do not establish the effectiveness of a compounded product.

See the Wegovy dosage guide for the label context.

STEP Trial Results: The Clinical Evidence

The STEP (Semaglutide Treatment Effect in People with Obesity) studies tested specified semaglutide regimens and lifestyle interventions.

The table summarizes group results; differences between separate trials do not isolate the effect of a dose, diabetes status or behavioral program.

STEP Trial Results: The Clinical Evidence
TrialParticipantsDurationAverage Weight LossKey Finding
STEP 11,961 adults with overweight or obesity, without diabetes68 weeks14.9% (vs 2.4% placebo)Both groups received lifestyle intervention
STEP 21,210 adults with overweight or obesity and type 2 diabetes68 weeks9.6% (vs 3.4% placebo)A separate population from STEP 1
STEP 3611 adults with overweight or obesity, without diabetes68 weeks16.0% (vs 5.7% placebo)Both groups received intensive behavioral therapy and an initial low-calorie diet
STEP 4902 entered run-in; 803 randomized20-week run-in, then 48 randomized weeks10.6% mean loss during run-in; then 7.9% further loss with continued semaglutide vs 6.9% regain after placebo switchChange after randomization is distinct from baseline-to-week-68 loss
STEP 5304 adults with overweight or obesity, without diabetes2 years15.2% (vs 2.6% placebo)Weight loss maintained over 2 years of continued treatment

The STEP 4 withdrawal trial compared continued semaglutide with switching to placebo after a 20-week run-in.

The separate STEP 1 extension followed a subset after semaglutide and lifestyle intervention stopped at week 68.

Over the following year, that semaglutide group regained about two-thirds of its prior loss.

These are different studies and group averages, not a prediction of what one person will regain. STEP 1 and STEP 3 also used different lifestyle programs.

What Affects Your Results?

Your treatment history and tolerability matter when interpreting trial averages. The trials below do not give a reliable personal forecast:

  • •Starting weight: A percentage and a number of pounds describe different things. The same percentage change represents more pounds at a higher starting weight; it does not predict who will respond.
  • •Dose and tolerability: The Wegovy label directs prescribers to consider treatment response and tolerability when selecting maintenance treatment. A higher dose is not automatically appropriate.
  • •Lifestyle support: In STEP 1, both groups received lifestyle intervention. In STEP 3, both received intensive behavioral therapy. Comparing their semaglutide averages does not measure the additional benefit of behavioral therapy.
  • •Trial population: STEP 2 studied adults with type 2 diabetes; STEP 1 did not. Their separate results are context for a clinical discussion, not proof that diabetes alone caused the difference.
  • •Individual response: Group averages include a range of outcomes. They cannot tell you the percentage you will lose or the month you will reach it.
  • •Treatment plan: Discuss missed doses and interruptions with your prescriber. Follow the product-specific instructions rather than changing the dose to match a trial result.

Semaglutide vs Tirzepatide: Which Produces Better Results?

SURMOUNT-5 directly compared weekly injections in 751 adults with obesity without diabetes for 72 weeks.

Participants received the maximum tolerated tirzepatide dose of 10 or 15 mg or semaglutide 1.7 or 2.4 mg:

Semaglutide vs Tirzepatide: Which Produces Better Results?
SURMOUNT-5Semaglutide injectionTirzepatide injection
Maximum tolerated weekly dose1.7 or 2.4 mg10 or 15 mg
Mean weight loss at week 7213.7%20.2%
Products outside this comparison7.2 mg, oral and compounded semaglutide were not studiedOral and compounded tirzepatide were not studied
Wegovy HD (7.2mg): approved March 2026

Wegovy HD is the 7.2 mg injection strength in the current prescribing information.

In the separate STEP UP trial, mean weight loss at 72 weeks was 18.7% with 7.2 mg under the treatment-policy analysis.

The as-intended analysis reported 20.7% with 7.2 mg versus 17.5% with 2.4 mg. About 31% assigned 7.2 mg achieved at least 25% loss in the main analysis, a different endpoint. STEP UP did not compare semaglutide with tirzepatide.

SURMOUNT-5's result applies to its studied doses and population. It does not establish a comparison with Wegovy 7.2 mg, oral products or compounded formulations.

Read the Wegovy vs Zepbound comparison for those boundaries, or compare semaglutide plan terms and, as a different medication, tirzepatide plan terms.

Oral GLP-1 Weight Loss Results: Pills vs Injections

Oral Wegovy and Foundayo are approved oral options alongside injectable treatment. The results below come from different studies with different formulations and endpoints.

Use them to understand the evidence for each option, not to rank pills against injections.

Oral GLP-1 Weight Loss Results: Pills vs Injections
OptionFormulationTrial Weight LossDurationKey Caveat
Injectable Wegovy 2.4mgWeekly injection14.9%68 weeks (STEP 1)Adults without diabetes; lifestyle intervention in both groups
Injectable Wegovy HD 7.2mgWeekly injection20.7% on-treatment (18.7% treatment-policy)72 weeks (STEP UP)Dose selection depends on response, tolerability and the approved indication
Oral Wegovy (semaglutide 25mg tablet)Daily pill, 30-min fast required13.6% (treatment-policy; 16.6% on-treatment)64 weeks (OASIS 4, NEJM)See Wegovy pill access and payment terms
Foundayo (orforglipron; 36 mg trial dose)Daily pill, no fasting11.2% (treatment-regimen; 12.4% efficacy estimand)72 weeks (ATTAIN-1, NEJM)Trial formulation differs from the commercial tablet; see Foundayo terms
ACHIEVE-3: Oral options head-to-head (T2D population)

The ACHIEVE-3 trial (N=1,698, 52 weeks, The Lancet 2026) compared the orforglipron 36 mg trial capsule against oral semaglutide 14mg in adults with type 2 diabetes.

Under the efficacy estimand, weight reduction was 9.2% versus 5.3%; the treatment-regimen analysis reported 8.2% versus 5.3%.

The FDA formulation review maps the 36 mg trial capsule to the bioequivalent commercial 17.2 mg tablet.

These strengths are a formulation distinction, not patient instructions.

ACHIEVE-3 used Rybelsus-level semaglutide doses, not the 25mg Wegovy pill dose, so it does not directly answer which obesity-approved pill produces more weight loss.

The practical decision: Oral Wegovy reported 13.6% at week 64 in OASIS 4 and requires a 30-minute fast; Foundayo reported 11.2% at week 72 on its highest trial dose in ATTAIN-1 and has no fasting requirement.

Those separate-trial averages are not a head-to-head result. Compare your prescribed product, dose, payment terms and coverage in the oral GLP-1 guide.

What Happens When You Stop Semaglutide?

In STEP 4, the 803 participants randomized after a 20-week semaglutide run-in had lost a mean 10.6%.

Over the next 48 weeks, those continuing semaglutide lost a further 7.9%, while those switched to placebo regained 6.9%. The continued-treatment group's 17.4% loss describes the full 68 weeks, not the first 20 weeks.

The separate STEP 1 extension followed 327 participants after semaglutide and lifestyle intervention stopped at week 68.

Over 52 weeks, the semaglutide group regained 11.6 percentage points, about two-thirds of its prior 17.3% loss in that subset.

This exploratory extension supports planning for possible regain with a clinician; it does not predict every patient's result.

Planning for Long-Term Use

Discuss how treatment will be reviewed over time and what to do if it becomes unaffordable or unsuitable.

Use the savings calculator to compare scenarios, then check semaglutide product, billing-period and upfront-payment terms.

Compounded products are not FDA-approved, and the branded withdrawal trials do not establish their outcomes.

How Do You Maximize Semaglutide Results?

  • •Follow your prescription: The Wegovy injection label uses gradual escalation and allows delays for tolerability. Use the instructions for your own product, and discuss dose changes with your prescriber.
  • •Ask for nutrition and activity guidance: STEP 1 and STEP 3 included lifestyle support. Ask your care team for protein, fluid and activity goals suited to your health rather than taking a trial average as a personal prescription.
  • •Agree on follow-up: Ask how your clinician will assess response, tolerability and whether treatment remains suitable. The dosing timeline tool helps organize questions; it does not select a dose.
  • •Report symptoms: Do not wait for a fixed number of weeks if symptoms are severe or persistent. The Wegovy patient information explains warning symptoms and when to seek medical help.

Getting Started: Cheapest Semaglutide Options

Start by comparing the semaglutide product and access route your prescriber considers appropriate. Price alone does not establish suitability or approval:

  • •Semaglutide plans: Compare semaglutide products, care inclusions and payment terms. Keep four-week billing, calendar-month billing and prepaid commitments distinct. The lowest advertised equivalent may require a larger upfront payment.
  • •Compounded semaglutide: See the post-shortage compounding restrictions. FDA's policy limits copying commercially available drugs after shortage resolution; it is not a blanket ban on every patient-specific compounded prescription. FDA advises that compounded drugs should be used only when an FDA-approved drug cannot meet a patient's medical needs. They are not FDA-approved, and affordability alone does not establish an appropriate compounding route.
  • •Brand-name semaglutide and coverage: Check Wegovy coverage and manufacturer savings terms. Eligibility and the prescribed product determine the available offer. For Wegovy HD, discuss suitability with your prescriber; the label bases dose selection on response and tolerability.
  • •Oral semaglutide: The Wegovy pill guide covers the approved tablet, administration requirements and current payment terms. An injection trial does not establish the result of a compounded oral product.
  • •Medicare: Medicare's weight-loss-drug coverage rules and the Medicare coverage guide distinguish ordinary Part D coverage from the separate GLP-1 Bridge and its eligibility requirements. Compounded semaglutide is not an approved Wegovy product.
  • •A different medication: If your prescriber is considering tirzepatide, use the Wegovy vs Zepbound evidence comparison and tirzepatide product and payment terms. Tirzepatide is a separate option, not a semaglutide access route.
  • •Compare care preferences: The provider match quiz organizes budget, insurance and service preferences. It does not determine clinical suitability or guarantee a prescription.

Frequently Asked Questions

How much weight will I lose on semaglutide in 3 months?

The cited trial averages cannot predict your three-month result. The Wegovy injection label still has dose escalation during the first 16 weeks, with possible delays for tolerability.

Your response may differ, and this schedule does not apply to oral or compounded semaglutide.

Do semaglutide results last?

STEP 5 found sustained group-average weight loss over two years of treatment, but continued treatment does not guarantee an individual's result.

In the separate STEP 1 extension, the semaglutide group regained about two-thirds of its prior loss during the year after treatment and lifestyle intervention stopped.

Discuss ongoing review and any stopping plan with your clinician.

Is semaglutide worth it?

That depends on your treatment goals, response, tolerability, medical history and cost. STEP 1 establishes an average benefit for its studied population, not a guarantee or an eligibility decision for you.

Review the Wegovy prescribing information and discuss benefits, risks and alternatives with a clinician.

What is Wegovy HD and how much weight can I lose on it?

Wegovy HD is the 7.2 mg injection strength. STEP UP reported 18.7% mean loss at 72 weeks under the treatment-policy analysis; the as-intended analysis reported 20.7% with 7.2 mg versus 17.5% with 2.4 mg.

About 31% assigned 7.2 mg achieved at least 25% loss in the main analysis. These are group endpoints, not your predicted result.

The label makes additional weight reduction, response and tolerability part of the prescriber's dose decision.

What are the most common side effects?

The Wegovy label lists nausea, diarrhea, vomiting and constipation among common reactions. There is no single deadline by which everyone's symptoms resolve.

Contact your clinician for severe or persistent symptoms, and follow the label's urgent-care instructions. The side effects guide provides more context.

Sources

Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.

Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.

Medicare & GLP-1

Medicare GLP-1 Coverage Guide

On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.

Read the Medicare guide →
Independent Clinical Perspective

What the doctors say

Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.

“Patients on both medications experienced substantial weight loss, and we observed no difference in the risk of gastrointestinal adverse events. In addition to effectiveness, factors like medication availability and insurance coverage will likely play a role in deciding which medication to initiate.”
Nicholas L. Stucky, MD, PhD, physician; co-author, real-world tirzepatide vs semaglutide study
Truveta Research / Providence Portland Medical Center
On real-world findings that practical factors matter beyond raw efficacy.
“For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing: offering a powerful new way to protect their hearts and improve their health.”
Helen Williams, Consultant pharmacist; National Clinical Director for Cardiovascular Disease Prevention
NHS England
NHS England announcing semaglutide (Wegovy) availability to cut heart attack and stroke risk.
NHS England ↗ · Apr 2026
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales. They are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
Sonya Babu-Narayan, Consultant cardiologist; Clinical Director, British Heart Foundation
British Heart Foundation
British Heart Foundation reacting to NICE recommending semaglutide for cardiovascular event prevention.

Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.

Featured Partners

Affiliate partners we feature. We may earn a commission.

Embody

Embody illustration of a compounded semaglutide injection vial
from $79/mo·Compounded

Compounded semaglutide injection, month to month; lowest plan price, may need a longer plan

Collective

Semaglutide options·Compounded

Gala

Gala provider illustration of compounded semaglutide injection vial
from $69/mo, billed yearly·Brand & Compounded

Compounded Semaglutide (yearly plan); annual plan, billed once a year; final price depends on state, dose and plan

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.